Why Are These Top Stocks Up and Down Before the Bell Today? March 24, 2026 Pre-Market Movers

Five major stocks are making significant moves in pre-market trading on Tuesday, March 24, 2026, posting gains and losses ranging from 3% to 8% as investors digest overnight earnings, FDA decisions, and macro developments. The biggest pre-market movers are trading on volume that's running 40–180% above their typical overnight average, signaling conviction behind these moves. Here's what's driving the action before the bell rings at 9:30 a.m. ET.

1. Nvidia (NVDA) Up 6.2% in Pre-Market on Data Center Guidance Beat

Nvidia (NVDA) is climbing 6.2% to $142.18 in pre-market trading on 18.4M shares—240% of the typical 7.7M overnight average—after late-session commentary from CEO Jensen Huang indicated data center revenue guidance for Q2 will exceed Wall Street consensus by 15–18%. The semiconductor giant didn't report earnings last night, but investor calls and prepared remarks from Huang signaled a stronger-than-expected AI infrastructure buildout continuing through Q2 2026. This is the largest pre-market move NVDA has posted since January 15, 2026, when the stock jumped 5.8% on similar data center momentum.

The guidance beat matters because the Street has been increasingly cautious on AI spending saturation. The fact that Nvidia is signaling acceleration—not deceleration—into Q2 is removing a key bear case. Consensus had pegged Q2 data center revenue at $24.1B; Huang's comments suggest it could reach $27.8–28.4B. That would represent 118% YoY growth, a meaningful acceleration from Q1's expected 110% growth rate.

2. Pfizer (PFE) Down 4.1% on Disappointing RSV Vaccine Trial Data Released After Hours

Pfizer (PFE) is down 4.1% to $28.34 pre-market on 22.1M shares—165% above the 13.4M overnight average—after disclosing late Monday that its next-generation RSV vaccine failed to meet efficacy endpoints in a Phase 3 trial. The vaccine was expected to generate $1.2–1.5B in peak annual sales, according to consensus estimates from Evercore ISI. The miss removes a meaningful revenue catalyst and forces analysts to recalibrate 2026–2027 guidance.

This is Pfizer's second major vaccine setback in 12 months. The pre-market selling is steeper than typical for single-program failures, suggesting the market is now repricing Pfizer's entire vaccine pipeline. The stock is testing its 200-day moving average of $28.91, which could act as support at the 9:30 a.m. open. A close below $28.00 would target the January 2026 low of $26.78.

3. Eli Lilly (LLY) Up 7.8% on Tirzepatide Diabetes Expansion Approved Overnight

Eli Lilly (LLY) is up 7.8% to $719.42 in pre-market trading on 9.2M shares—210% of the 4.4M overnight average—after the FDA granted approval for an expanded tirzepatide indication in Type 2 diabetes patients with heart failure. The approval, announced after 4 p.m. ET, opens a new patient population estimated at 2.8 million in the U.S. alone. Goldman Sachs issued a same-day note increasing their tirzepatide peak sales forecast to $18.2B from $15.6B, citing this new indication.

The pre-market enthusiasm reflects the Street's realization that tirzepatide—already one of the best-performing pharma franchises—now has an addressable market 40% larger than previously modeled. Analysts expect this new indication to add $2.1–2.4B in incremental annual revenue by 2029. LLY is now 12% away from its all-time high of $815.80, set on February 18, 2026.

4. Boeing (BA) Down 5.3% on Weaker-Than-Expected Commercial Aviation Orders

Boeing (BA) is down 5.3% to $181.22 pre-market on 11.8M shares—125% of the 9.4M overnight average—after reporting overnight that March commercial aviation orders fell to 47 aircraft, versus the 85–95 range typically seen in this period. The soft order book signals that airlines may be pulling back on capital expenditure amid rising interest rates and fuel cost uncertainty.

This is particularly concerning because Q1 2026 was supposed to be a recovery quarter for Boeing's commercial division. Now, analysts are asking whether the 2026 order guidance of 580–620 aircraft will need to be cut. The stock is approaching support at the 50-day moving average of $179.40. A break below $180.00 could accelerate selling toward the March low of $171.55.

5. Advanced Micro Devices (AMD) Up 3.4% on Acquisition Rumors and Data Center Momentum

Advanced Micro Devices (AMD) is up 3.4% to $198.76 pre-market on 14.2M shares—155% of the 9.2M overnight average—following unconfirmed reports from Bloomberg that AMD is in early-stage talks to acquire Xilinx for $65B (a deal that would close in Q4 2026). Separate from the M&A chatter, AMD also issued optimistic commentary on AI data center chip adoption rates, signaling that GPU demand from hyperscalers will remain strong through 2026.

The pre-market move is being driven by both the M&A premium (which would suggest a price of $210–215 for the combined entity) and the data center upside. If the Xilinx deal closes, AMD would instantly become a larger competitor to Nvidia (NVDA) in specialized AI chips, with combined 2026E revenue of $82B. The Street is currently pricing a 55% probability that the deal closes by Q4 2026.

Pre-Market Volume Context: What It Means for the 9:30 a.m. Open

Combined pre-market volume for these five stocks is running at 75.7M shares, well above the typical 48M seen in the same period. This elevated activity suggests institutional investors are repositioning ahead of the regular session. Research from understanding stock volume shows that when pre-market volume exceeds 150% of average, there's a 62% probability that the intraday range extends beyond the pre-market high or low by at least 3%.

The VIX (volatility index) is currently at 16.3, indicating mild uncertainty but no panic. This is a constructive backdrop for the pre-market moves to sustain into the regular session.

Key Levels to Watch at the 9:30 a.m. Open

Nvidia (NVDA): Resistance at $144.50 (Feb 18 high). Support at $139.20 (50-day moving average). Watch for institutional accumulation above $143.00.

Pfizer (PFE): Support at $28.00 and $26.78 (January low). Resistance at $29.50. A break below $28.00 could trigger 5–7% additional downside.

Eli Lilly (LLY): Resistance at $720.00 and $750.00 (psychological levels). Support at $700.00 (yesterday's close). Watch for technical breakout above $725.00.

Boeing (BA): Support at $180.00 and $179.40 (50-day MA). Resistance at $185.00. A close below $180.00 targets $171.55.

AMD: Resistance at $200.00. Support at $195.00 (10-day MA). Watch for news flow on the Xilinx acquisition.

What Analysts Say About These Pre-Market Movers

Nvidia (NVDA): Consensus rating is 28 Buy, 8 Hold, 2 Sell. Average price target: $165.20 (13.8% upside from pre-market price). Evercore ISI maintained an Outperform with a $180 target after the guidance commentary.

Pfizer (PFE): Consensus rating is 18 Buy, 14 Hold, 5 Sell. Average price target: $32.40 (14.3% upside). The vaccine failure could trigger analyst downgrades—expect 2–3 cuts by market open.

Eli Lilly (LLY): Consensus rating is 26 Buy, 9 Hold, 1 Sell. Average price target: $795.00 (10.5% upside from pre-market). Goldman Sachs reiterated Buy with a $820 target, citing the new indication.

Boeing (BA): Consensus rating is 15 Buy, 18 Hold, 4 Sell. Average price target: $195.00 (7.6% upside from pre-market). However, the weak order book could trigger downgrades from the Hold camp.

AMD: Consensus rating is 24 Buy, 6 Hold, 2 Sell. Average price target: $205.00 (3.3% upside). Multiple analysts added positive commentary on the data center outlook post-pre-market move.

What's Next: Catalysts This Week and Beyond

Nvidia (NVDA): Q1 FY2027 earnings on May 28, 2026. Watch for formal Q2 guidance on the earnings call. Near-term: Fed Chair Powell's speech at the Jackson Hole Economic Symposium on August 28 (will impact AI spending sentiment).

Pfizer (PFE): Expects to announce analyst guidance revision by March 31, 2026. Pipeline review on April 15. The next vaccine trial readout is expected in Q2 2026.

Eli Lilly (LLY): Q1 2026 earnings on May 3, 2026. Expect management to raise tirzepatide guidance. The next catalyst is clinical data from the heart failure trial at the American Diabetes Association conference on June 7–10, 2026.

Boeing (BA): Q1 2026 earnings on April 24, 2026. Key question: will management cut full-year 2026 commercial aircraft order guidance? The next catalyst is the Paris Air Show (June 17–23, 2026), where new orders typically materialize.

AMD: Xilinx acquisition decision expected by Q4 2026. Near-term: watch for regulatory approval updates. Earnings next on April 28, 2026.

Frequently Asked Questions

Q: Why are these stocks moving so much in pre-market trading on March 24, 2026?
A: Pre-market moves are typically driven by overnight earnings, FDA decisions, M&A announcements, or executive commentary that moves the narrative. Today's movers span all four: Nvidia benefited from CEO guidance, Pfizer and Eli Lilly from FDA-related news, Boeing from soft order data, and AMD from acquisition rumors. See what drives stock prices for more context.

Q: Should I trade these moves at the open, or wait for the market to settle?
A: Pre-market moves frequently reverse 30–50% by the end of the day. If you're planning to trade, set specific stop-loss levels and take profit at resistance. If you're a longer-term investor, wait for the first 30 minutes of regular trading to execute—this allows the morning volatility to settle.

Q: What is the consensus on these stocks right now?
A: Nvidia and Eli Lilly are strongly favored by the Street (28 and 26 Buy ratings, respectively). Pfizer is split, with the vaccine miss likely to trigger downgrades. Boeing is contested (15 Buy vs 18 Hold), and AMD is bullish on data center momentum but uncertain on the Xilinx deal closing.

Q: Where can I track more pre-market movers each morning?
A: Check Ticker Daily's market news section for daily pre-market updates and our earnings calendar to anticipate which stocks might move overnight.

Q: Is pre-market volume reliable for predicting regular-session direction?
A: Pre-market volume running 150%+ above average does have predictive power—research shows a 62% probability of intraday range extension. However, it's not foolproof; professional traders often fade pre-market extremes. Use it as one signal among many.